Letter From The Editor

Adipocytes, hormones, pro-hormones, cytokines and enzymes are all found in adipose tissue but what does this have to do with the endocrine system? Can they affect total-body metabolism and cardiovascular health? This week our excerpt from the JOSLIN’S DIABETES DESKBOOK – A Guide for Primary Care Providers, Updated 2nd Edition, …

Many of us have been seeing patients for a long time and as we squeeze more patients into each hour to be profitable, there is an increasing risk of burnout. This burnout can lead to misdiagnoses according to Dr. Paul Griner, MD, and past president of the American College of …

This past weekend I delivered a talk on "Provider Evolution: Medical Homes and Accountable Care Organizations (ACOs)" to a large group of medical professionals. Two of the slides stood out like big red bullseyes. The first ranked the overall quality of health care among seven of the world’s most progressive …

There are some looming issues in reimbursement for healthcare coming in the next year. If things don’t change prescribers will be faced with a 27% decrease in reimbursement rates for Medicare and Medicaid patients, and many of the practitioners I talk to tell me that they will no longer take …

Each week we try to bring you useful information on how to improve your patients’ care. Most of us have come to realize that no one method or idea works for every patient so when our staff selects information for you we try to bring you solutions and ideas from …

Hope everyone had a great Thanksgiving and that you found everything you wanted during your Black Friday shopping spree. During the recent Liver Meeting 2012 in Boston there was a presentation on the apparent increase in the risk of liver disease and cirrhosis in type 1 patients. With this in …

According to dictionary.com, "iatrogenic" is defined as an adverse effect induced in a patient as the result of a physician’s words or actions, especially as a consequence of taking a drug prescribed by the physician. No other drug causes more iatrogenic events than insulin. This week our Clinical Text discusses the …

As we try to address the burgeoning problem of diabetes worldwide, studies dealing with food choices or physical activity always catch our attention. We want to take advantage of the results and apply them to patients regardless of whether the study participants even have diabetes. Even if the trial has only …

Last week we reported that the FDA advisory board had given their blessing to the new long-acting insulin, degludec. However, trying to find good information about this product, how it works, and what makes it different from insulin glargine or insulin detimir, has been next to impossible. This week, our …

This week week the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommended that degludec, Novo’s new long acting insulin, be approved for use in the United States. There was a lot of the usual fuss about CV studies that seems to go along with with every new diabetes drug, but this …